WBR0478: Difference between revisions

Jump to navigation Jump to search
Rim Halaby (talk | contribs)
Created page with "{{WBRQuestion |QuestionAuthor={{Rim}} |ExamType=USMLE Step 1 |MainCategory=Microbiology, Pharmacology |SubCategory=Dermatology |MainCategory=Microbiology, Pharmacology |SubCat..."
 
WikiBot (talk | contribs)
m refreshing WBR questions
 
(8 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{WBRQuestion
{{WBRQuestion
|QuestionAuthor={{Rim}}
|QuestionAuthor= {{YD}} (Reviewed by  {{YD}} and  {{AJL}})
|ExamType=USMLE Step 1
|ExamType=USMLE Step 1
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
Line 8: Line 8:
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Dermatology
|SubCategory=Dermatology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
Line 20: Line 21:
|MainCategory=Microbiology, Pharmacology
|MainCategory=Microbiology, Pharmacology
|SubCategory=Dermatology
|SubCategory=Dermatology
|Prompt=A 42 year old female patient presents to the dermatology clinic with a complaint of nail lesion. Following appropriate work-up, the diagnosis of onychomycosis is made. She was prescribed an antimicrobial medication that was then stopped due to alteration of liver function tests. What is the mechanism of action that best describes the medication prescribed for this patient?
|Prompt=A 72-year-old diabetic woman presents to the dermatology clinic with complaints of a nail lesion. Following history-taking and physical examination, the patient is diagnosed with onychomycosis. She is then prescribed an oral antimicrobial medication and is instructed to follow-up routinely. One month later, the patient reports she is experiencing an unusual taste disturbance; and she is found to have markedly elevated liver function tests. Which of the following best describes the mechanism of action of the prescribed antimicrobial agent?
|Explanation=Terbinafine is considered first line treatment for onychomycosis. Terbinafine is an antifungal that inhibits squalene epoxidase. Its most common side effects are altered liver function tests (LFTs) and visual disturbance. Patients are usually requested to routinely perform LFT testing during treatment with terbinafine to monitor to drug-induced liver injury (DILI).
|Explanation=[[Onychomycosis]] is a common fungal infection of the nail apparatus. Although it is usually only a cosmetic concern, treatment of onychomyocis is very difficult and often necessitates systemic [[antifungal therapy]]. Onychomycosis typically affects older patients with co-morbidities, such as [[diabetes mellitus]], [[HIV]], [[trauma]], and [[peripheral vascular disease]]. If left untreated, onychomycosis results in toe pain, spreads to other adjacent toe nails, and may be complicated by superimposed bacterial infections (erysipelas and cellulitis) and ingrown nails. The most common cause of onychomycosis is ''Trichophyton rubrum''. Treatment options classically included [[griseofulvin]] and [[ketoconazole]]; but newer antifungals, such as [[fluconazole]], [[itraconazole]], and [[terbinafine]], are currently available and more efficacious. [[Terbinafine]] is now considered a first line treatment for [[onychomycosis]]. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase. It is present in both topical and oral forms. Classical adverse drug reactions associated with oral [[terbinafine]] are altered [[liver function test]]s (LFTs), GI upset, and taste disturbances. During treatment with [[terbinafine]], patients are instructed to routinely perform LFT testing to monitor to [[drug-induced liver injury]] (DILI) that usually occurs within the first 6 months of terbinafine therapy and generally resolves within 3-6 months of drug discontinuation.
 
Educational Objective:
Terbinafine is first line treatment for onychomycosis.  It is an antifungal that inhibits squalene epoxidase.  Liver injury is a potential side effect of terbinafine.
|AnswerA=Inhibits squalene epoxidase
|AnswerA=Inhibits squalene epoxidase
|AnswerAExp=Terbinafine is a squalene epoxidase inhibitor. It is the first line treatment for onychomycosis. Liver function tests must be monitored due to terbinafine's hepatic adverse reaction.
|AnswerAExp=[[Terbinafine]] is now considered a first line treatment for [[onychomycosis]]. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase.
|AnswerB=Inhibits DNA polymerase  
|AnswerB=Inhibits DNA polymerase
|AnswerBExp=Several antiviral medications inhibit DNA polymerase.  They are not used to treat onychomycosis.
|AnswerBExp=Several antiviral medications, which are not used to treat onychomycosis, inhibit DNA polymerase.
|AnswerC=Inhibits aminoacyl-tRNA attachment
|AnswerC=Inhibits aminoacyl-tRNA attachment
|AnswerCExp=Tetracyclines inhibit aminoacyl-tRNA attachment.  They are not used to treat onychomycosis.
|AnswerCExp=Tetracyclines, which are not used to treat onychomycosis, inhibit aminoacyl-tRNA attachment.
|AnswerD=Inhibits synthesis of beta-glucan
|AnswerD=Inhibits synthesis of beta-glucan
|AnswerDExp=Caspofungin inhibits synthesis of beta-glucan.  It is not used to treat onychomycosis.
|AnswerDExp=Caspofungin, which is not used to treat onychomycosis, inhibits synthesis of beta-glucan.
|AnswerE=Inhibits ergosterol synthesis
|AnswerE=Inhibits ergosterol synthesis
|AnswerEExp=Azoles inhibit ergosterol synthesis. They are not used to treat onychomycosis.
|AnswerEExp=Azoles inhibit ergosterol synthesis and may be administered to treat onychomycosis; but the patient's symptoms and history are more consistent with terbinafine adverse reactions.
|EducationalObjectives=[[Terbinafine]] is now considered a first line treatment for [[onychomycosis]]. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase. Classical adverse drug reactions to oral [[terbinafine]] are altered liver function tests (LFTs), GI upset, and taste disturbances.
|References=de Sa DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15(1):17-36.<br>
First Aid 2014 page 190
|RightAnswer=A
|RightAnswer=A
|WBRKeyword=terbinafine, drug, induced, liver, injury, DILI, adverse, reaction, side, effect, adverse drug reaction, side effect, antifungal, onychomycosis, liver, function, test, LFT, liver functon test
|WBRKeyword=Terbinafine, Drug induced liver injury, Hepatotoxicity, Adverse drug reaction, Adverse drug event, Side effect, Squalene epoxidase, Onychomycosis, Antifungals
|Approved=No
|Approved=Yes
}}
}}

Latest revision as of 00:42, 28 October 2020

 
Author [[PageAuthor::Yazan Daaboul, M.D. (Reviewed by Yazan Daaboul, M.D. and Alison Leibowitz [1])]]
Exam Type ExamType::USMLE Step 1
Main Category MainCategory::Microbiology, MainCategory::Pharmacology
Sub Category SubCategory::Dermatology
Prompt [[Prompt::A 72-year-old diabetic woman presents to the dermatology clinic with complaints of a nail lesion. Following history-taking and physical examination, the patient is diagnosed with onychomycosis. She is then prescribed an oral antimicrobial medication and is instructed to follow-up routinely. One month later, the patient reports she is experiencing an unusual taste disturbance; and she is found to have markedly elevated liver function tests. Which of the following best describes the mechanism of action of the prescribed antimicrobial agent?]]
Answer A AnswerA::Inhibits squalene epoxidase
Answer A Explanation [[AnswerAExp::Terbinafine is now considered a first line treatment for onychomycosis. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase.]]
Answer B AnswerB::Inhibits DNA polymerase
Answer B Explanation AnswerBExp::Several antiviral medications, which are not used to treat onychomycosis, inhibit DNA polymerase.
Answer C AnswerC::Inhibits aminoacyl-tRNA attachment
Answer C Explanation AnswerCExp::Tetracyclines, which are not used to treat onychomycosis, inhibit aminoacyl-tRNA attachment.
Answer D AnswerD::Inhibits synthesis of beta-glucan
Answer D Explanation AnswerDExp::Caspofungin, which is not used to treat onychomycosis, inhibits synthesis of beta-glucan.
Answer E AnswerE::Inhibits ergosterol synthesis
Answer E Explanation AnswerEExp::Azoles inhibit ergosterol synthesis and may be administered to treat onychomycosis; but the patient's symptoms and history are more consistent with terbinafine adverse reactions.
Right Answer RightAnswer::A
Explanation [[Explanation::Onychomycosis is a common fungal infection of the nail apparatus. Although it is usually only a cosmetic concern, treatment of onychomyocis is very difficult and often necessitates systemic antifungal therapy. Onychomycosis typically affects older patients with co-morbidities, such as diabetes mellitus, HIV, trauma, and peripheral vascular disease. If left untreated, onychomycosis results in toe pain, spreads to other adjacent toe nails, and may be complicated by superimposed bacterial infections (erysipelas and cellulitis) and ingrown nails. The most common cause of onychomycosis is Trichophyton rubrum. Treatment options classically included griseofulvin and ketoconazole; but newer antifungals, such as fluconazole, itraconazole, and terbinafine, are currently available and more efficacious. Terbinafine is now considered a first line treatment for onychomycosis. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase. It is present in both topical and oral forms. Classical adverse drug reactions associated with oral terbinafine are altered liver function tests (LFTs), GI upset, and taste disturbances. During treatment with terbinafine, patients are instructed to routinely perform LFT testing to monitor to drug-induced liver injury (DILI) that usually occurs within the first 6 months of terbinafine therapy and generally resolves within 3-6 months of drug discontinuation.

Educational Objective: Terbinafine is now considered a first line treatment for onychomycosis. It is an anti-fungal medication that selectively inhibits fungal squalene epoxidase. Classical adverse drug reactions to oral terbinafine are altered liver function tests (LFTs), GI upset, and taste disturbances.
References: de Sa DC, Lamas AP, Tosti A. Oral therapy for onychomycosis: an evidence-based review. Am J Clin Dermatol. 2014;15(1):17-36.
First Aid 2014 page 190]]

Approved Approved::Yes
Keyword WBRKeyword::Terbinafine, WBRKeyword::Drug induced liver injury, WBRKeyword::Hepatotoxicity, WBRKeyword::Adverse drug reaction, WBRKeyword::Adverse drug event, WBRKeyword::Side effect, WBRKeyword::Squalene epoxidase, WBRKeyword::Onychomycosis, WBRKeyword::Antifungals
Linked Question Linked::
Order in Linked Questions LinkedOrder::